Aura Biosciences AURA
NASDAQ AURA
$7.56 +0.19 (+2.58%)
As of: Sep 4, 2026 · 3:59 PM EDT

Aura Biosciences (AURA) Non-Current Deffered Revenue (2020)

Aura Biosciences' (AURA) quarterly Non-Current Deffered Revenue came in at $8000.0 in Q4 2020.

Analysis

Aura Biosciences (AURA) Non-Current Deffered Revenue (2020) Analysis & Trends

Aura Biosciences (AURA) has 1 years of Non-Current Deffered Revenue data on file, last reported at $8000.0 in Q4 2020.

  • Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $8000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $8000.0 (changed N/A YoY) and the FY2020 annual result came in at $8000.0, changed N/A from the prior year.
  • Non-Current Deffered Revenue held at $8000.0 in Q4 2020.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $8000.0 in Q4 2020 to a low of $8000.0 in Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Aura Biosciences 717.17 Mn 649.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 8,000.00